Vaccine therapies for chronic hepatitis B: can we go further?
Chronic hepatitis B is a major health burden worldwide. In addition to the recent progress in antiviral treatment, therapeutic vaccination is a promising new strategy for the control of chronic hepatitis B. On the basis of the major specific and non-specific immune dysregulations and defects in chronic hepatitis B patients, this paper presents the peptide and protein-based, DNA-based, cell-based, and antigen-antibody-based therapeutic vaccines, which have undergone clinical trials. The advantages, disadvantages, and future perspectives for these therapeutic vaccines are discussed.
Key Laboratory Medical Molecular Virology of Ministry of Education/Ministry of Health, Shanghai Medical College, Fudan University, Shanghai, 200032, China, ymwen@shmu.edu.cn.
Yumei
Y
Wen
Xuanyi
X
Wang
Bin
B
Wang
Zhenhong
Z
Yuan
D017325:Hepatitis B Vaccines / Q000276:immunology / Q000627:therapeutic use*; D006515:Hepatitis B virus / Q000276:immunology; D019694:Hepatitis B, Chronic / Q000276:immunology / Q000628:therapy*; D006801:Humans
D017325:Hepatitis B Vaccines